Search for: All records

Foundation Models (FMs) are gaining increasing attention in the biomedical artificial intelligence (AI) ecosystem due to their ability to represent and contextualize multimodal biomedical data. These capabilities make FMs a valuable tool for a variety of tasks, including biomedical reasoning, hypothesis generation, and interpreting complex imaging data. In this review paper, we address the unique challenges associated with establishing an ethical and trustworthy biomedical AI ecosystem, with a particular focus on the development of FMs and their downstream applications. We explore strategies that can be implemented throughout the biomedical AI pipeline to effectively tackle these challenges, ensuring that these FMs are translated responsibly into clinical and translational settings. Additionally, we emphasize the importance of key stewardship and co-design principles that not only ensure robust regulation but also guarantee that the interests of all stakeholders—especially those involved in or affected by these clinical and translational applications—are adequately represented. We aim to empower the biomedical AI community to harness these models responsibly and effectively. As we navigate this exciting frontier, our collective commitment to ethical stewardship, co-design, and responsible translation will be instrumental in ensuring that the evolution of FMs truly enhances patient care and medical decision-making, ultimately leading to a more equitable and trustworthy biomedical AI ecosystem. 

Cancer screening is a large, population-based intervention that would benefit from tools enabling individually-tailored decision making to decrease unintended consequences such as overdiagnosis. The heterogeneity of cancer screening participants advocates the need for more personalized approaches. Partially observable Markov decision processes (POMDPs) can be used to suggest optimal, individualized screening policies. However, determining an appropriate reward function can be challenging. Here, we propose the use of inverse reinforcement learning (IRL) to form rewards functions for lung and breast cancer screening POMDP models. Using data from the National Lung Screening Trial and our institution's breast screening registry, we developed two POMDP models with corresponding reward functions. Specifically, the maximum entropy (MaxEnt) IRL algorithm with an adaptive step size was used to learn rewards more efficiently; and combined with a multiplicative model to learn state-action pair rewards in the POMDP. The lung and breast cancer screening models were evaluated based on their ability to recommend appropriate screening decisions before the diagnosis of cancer. Results are comparable with experts' decisions. The lung POMDP demonstrated an improved performance in terms of recall and false positive rate in the second screening and post-screening stages. Precision (0.02-0.05) was comparable to experts' (0.02-0.06). The breast POMDP has excellent recall (0.97-1.00), matching the physicians and a satisfactory false positive rate (<0.03). The reward functions learned with the MaxEnt IRL algorithm, when combined with POMDP models in lung and breast cancer screening, demonstrate performance comparable to experts.